VARIQUEL

This brand name is authorized in Ireland, Malta, New Zealand, United Kingdom

Active ingredients

The drug VARIQUEL contains one active pharmaceutical ingredient (API):

1 Terlipressin
UNII 4U092XZF0K - TERLIPRESSIN ACETATE

Terlipressin inhibits portal hypertension with simultaneous reduction of blood circulation in portal vessels. Terlipressin contracts smooth oesophageal muscle with consecutive compression of oesophageal varices.

Read about Terlipressin

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
VARIQUEL Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
H01BA04 Terlipressin H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01B Posterior pituitary lobe hormones → H01BA Vasopressin and analogues
Discover more medicines within H01BA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 176347, 240964
Country: MT Medicines Authority Identifier(s): AA565/28402
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 21323

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.